Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Trial Profile

A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Momelotinib (Primary) ; Ruxolitinib
  • Indications Anaemia; Myelofibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms Simplify 1
  • Sponsors Gilead Sciences; Sierra Oncology
  • Most Recent Events

    • 30 Jan 2024 According to GlaxoSmithKline media release,company announces that health canada has accepted into review the New Drug Submission(NDS) for momelotinib, follows that of the Ministry of Health, Labour and Welfare (WHLW) in Japan and approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).The NDS is based on key phase III trials SIMPLIFY-1 and MOMENTUM
    • 12 Dec 2023 Results of pooled analysis from SIMPLIFY-1 and SIMPLIFY-2 , applying time without transfusion reliance (TWiTR) analyses, integrating transfusion-dependent (TD) status and OS, to further characterize the benefits of MMB on survival quality.presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results demonstrating the prognostic influence of RBC transfusion status and other covariates on overall survival SIMPLIFY-1 (S1), SIMPLIFY-2 (S2), and MOMENTUM studies presented at the 65th American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top